Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2026 02:00 ET | Source: Avacta Group PLC

Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis

Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu® Clinical trial with AVA6103 is expected to be initiated...
February 23, 2026 17:10 ET | Source: Kyntra Bio

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer...
February 23, 2026 08:50 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board

TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel...
February 23, 2026 08:30 ET | Source: Sutro Biopharma, Inc.

Sutro Biopharma Announces Participation at the 16th World ADC London Summit

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
February 23, 2026 08:00 ET | Source: Artios Pharma

Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer

Artios receives FDA Fast Track designation for DNA polymerase theta (Polθ) inhibitor ART6043 for treatment of gBRCA-mutated HER2-negative breast cancer
February 20, 2026 08:30 ET | Source: PDS Biotechnology Corporation

PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval

PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
February 19, 2026 10:48 ET | Source: Research and Markets

Claudin 18.2-Targeted Immunotherapy Pipeline Market Research Report 2026: an Up-to-date Competitor Evaluation in the Field of Therapy Candidates in Research and Development

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Claudin 18.2-Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
February 19, 2026 10:14 ET | Source: Research and Markets

Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Market Review 2025: Regional, Phase, Sponsor & Enrollment Analysis with G7 & E7 Coverage and Five-Year Trend Review

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Gastroesophageal (GE) Junction Carcinomas - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's...
February 19, 2026 09:39 ET | Source: Research and Markets

Cancer & Antibody Conjugates Patent Landscape Analysis 2025: 3761 Patent Families - IP Trends, Including Time Evolution of Published Patents and Countries of Patent Filings

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Cancer & Antibody Conjugates Patent Landscape Analysis 2025" report has been added to ResearchAndMarkets.com's offering.Key Features: PDF >...
February 19, 2026 09:00 ET | Source: Broadcom Inc.

Broadcom Introduces Industry’s First 6G Digital Front-End SoC for Massive MIMO

PALO ALTO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Broadcom Inc. (NASDAQ: AVGO), a global technology leader that designs, develops and supplies semiconductor and infrastructure software solutions,...